Becton, Dickinson and Company (NYSE:BDX – Get Free Report) EVP Michael Feld sold 76 shares of Becton, Dickinson and Company stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $198.13, for a total value of $15,057.88. Following the sale, the executive vice president owned 19,568 shares of the company’s stock, valued at approximately $3,877,007.84. This represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Feld also recently made the following trade(s):
- On Monday, September 28th, Michael Feld sold 76 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $183.70, for a total value of $13,961.20.
- On Wednesday, August 26th, Michael Feld sold 165 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $188.49, for a total value of $31,100.85.
Becton, Dickinson and Company Price Performance
Shares of BDX opened at $194.91 on Thursday. The firm has a market cap of $53.71 billion, a PE ratio of 58.71, a PEG ratio of 13.41 and a beta of 0.21. The firm’s 50 day moving average price is $186.17 and its 200 day moving average price is $170.31. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $200.47.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last posted its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the company earned $3.68 earnings per share. The company’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Becton, Dickinson and Company in the second quarter valued at $3,721,533,000. Bank of America Corp DE bought a new position in shares of Becton, Dickinson and Company during the second quarter valued at $474,993,000. First Eagle Investment Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after acquiring an additional 1,887,224 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at $247,372,000. Finally, Deutsche Bank AG acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at $204,226,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on BDX shares. Wolfe Research started coverage on shares of Becton, Dickinson and Company in a report on Tuesday, October 20th. They issued an “outperform” rating for the company. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Zacks Research raised Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a research note on Friday, August 7th. Finally, Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $185.07.
Read Our Latest Analysis on BDX
About Becton, Dickinson and Company
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.
BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
